Abbott Laboratories v. Gardner

Background

A group of 37 prescription drug manufacturers and their trade association challenged a Food and Drug Administration rule requiring the drug’s official “established name” to appear every time a trade (proprietary) name is used on labels, ads, and printed material. The companies argued the Commissioner exceeded his authority. The District Court sided with the manufacturers, but the Court of Appeals reversed, holding that pre-enforcement review was not available and that no case or controversy existed.

Reasoning

The Court held that Congress did not clearly bar pre-enforcement judicial review. It relied on the Administrative Procedure Act’s presumption favoring review and on a saving clause in the Food, Drug, and Cosmetic Act. The Court found the Commissioner’s labeling rule to be a final agency action made after formal notice and comment, a purely legal question fit for decision, and one that imposes immediate, concrete obligations on manufacturers. Because the regulation forces companies to choose between costly compliance and risking criminal or civil penalties, the Court allowed judicial review and sent the case back to the Court of Appeals for a full merits review.

Real world impact

The decision lets drug companies seek court rulings before the government enforces labeling rules, relieving them of the immediate dilemma of reprinting materials or risking prosecution. The Supreme Court did not rule on whether the labeling rule itself is lawful; it only held that courts may hear such pre-enforcement challenges and remanded the case for further review.

Dissents or concurrances

The opinion notes separate dissenting opinions by Justices Fortas and Clark, who disagreed with the majority’s conclusions, but the opinion does not detail their arguments here.